A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis.

Trial Profile

A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2012

At a glance

  • Drugs Folic acid; Methotrexate; Vidofludimus
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPONENT
  • Most Recent Events

    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 07 Nov 2011 Status changed from active, no longer recruiting to completed, according to a 4SC media release.
    • 08 Jun 2011 Primary endpoint 'American-College-of-Rheumatology-20%-response-criteria' at week 13 has not been met, according to information in a 4SC media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top